secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-123925
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura secures $250K loan from AD Pharma, extends LTX-03 NDA deadline to March 2024, warns of possible bankruptcy
--------------------------------------------------------------------------------

- Received $250,000 loan from AD Pharma (owns ~66% of stock), bringing total debt to $4,669,279 at 5.25% interest, due Dec 31, 2023.
- If not repaid, default interest rises to 7.5%; company states without additional funding it will scale back or cease operations.
- Amended LTX-03 development deal: FDA NDA acceptance deadline extended to March 31, 2024; AD Pharma can terminate anytime.
- If NDA not accepted by March 31, 2024, AD Pharma may take over LTX-03 intellectual property.
- AD Pharma, controlled by John Schutte, also holds warrants for 10M shares; Schutte directly owns ~14% of Acura.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465923123925/0001104659-23-123925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465923123925/tm2332252d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer